Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2% – Should You Sell?

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA)’s stock price fell 2.2% during mid-day trading on Tuesday . The stock traded as low as $1.7612 and last traded at $1.78. 5,402 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 19,733 shares. The stock had previously closed at $1.82.

Analyst Ratings Changes

IPHA has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of Innate Pharma in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Finally, HC Wainwright set a $5.00 price objective on shares of Innate Pharma and gave the company a “buy” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Innate Pharma has an average rating of “Moderate Buy” and an average price target of $5.00.

Innate Pharma Trading Down 2.2%

The company’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.95.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.